Clinical Research Directory

Inclusion Criteria: * 18 years or older * ECOG or WHO performance status 0 or 1 * Diagnosis of resectable iCCA on imaging. No histological confirmation is needed before surgery, according to standard of care. * Patient is able to undergo a laparotomy. * Positioning of a catheter for HAIP chemotherapy is technically feasible based on a CT-scan with early arterial phase with 1mm cuts. The default site for the catheter insertion is the GDA. Accessory or aberrant hepatic arteries are no contraindication for catheter placement. * Adequate bone marrow, liver, and renal function before inclusion (values may be max. 30 days old) * Absolute neutrophil count (ANC) ≥ 1.5 x 10\^ 9/L * White blood cell count (WBC) ≥ 2.5 x 10\^9/L * Platelets ≥ 100 x 10\^9/L * Glomerular filtration rate (GFR) ≥ 30 ml/min * Haemoglobin (Hb) ≥ 5.5 mmol/L * Total bilirubin ≤ 25 µmol/L * Written informed consent must be given according to ICH/good clinical practice (GCP), and national/local regulations. Exclusion Criteria: * Presence of extrahepatic disease at the time of first presentation. Patients with locoregional lymph node disease or with small (≤ 1 cm) extrahepatic lesions that are too small to characterize or biopsy are eligible. * Second primary malignancy, except for adequately treated non-melanoma skin cancer, or other malignancy treated at least 3 years previously without evidence of recurrence or with a life expectancy longer than 5 years. * Known homozygous dihydropyrimidine dehydrogenase (DPYD) deficiency * Prior hepatic radiation, ablation, or resection for iCCA. * Clinical evidence of portal hypertension (ascites, gastroesophageal varices, or portal vein thrombosis). Some postoperative ascites is allowed. * (Partial) portal vein thrombosis in future liver remnant. * Pregnant or lactating women. * History of psychiatric disability judged by the investigator to be clinically significant, precluding informed consent or interfering with compliance for HAIP chemotherapy. * Serious concomitant systemic disorders that would compromise the safety of the patient or his/her ability to complete the study, at the discretion of the investigator. * Organ allografts requiring immunosuppressive therapy. * Serious infections (uncontrolled or requiring treatment). * Participation in another interventional study for iCCA with survival as outcome. * Participation in another prospective study with an interventional medical product. * Any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule; those conditions should be discussed with the patient before registration in the trial